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Abstract Characterizing the relationship between genetic, epigenetic (e.g., deoxyribonucleic acid
[DNA] methylation), and transcript variation could provide insights into mechanisms
regulatinghemostasis andpotentially identify newdrug targets. Several hemostatic factors
are synthesized in the liver, yet high-resolution DNA methylation data from human liver
tissue is currently lacking for these genes. Single-nucleotide polymorphisms (SNPs) can
inﬂuence DNA methylation in cis which can affect gene expression. This can be analyzed
through allele-speciﬁc methylation (ASM) experiments. We performed targeted genomic
DNA- and bisulﬁte-sequencing of 35 hemostatic genes in human liver samples for SNP and
DNA methylation analysis, respectively, and integrated the data for ASM determination.
ASM-associated SNPs (ASM-SNPs) were tested for association to gene expression in liver
using in-house generated ribonucleic acid-sequencing data. We then assessed whether
ASM-SNPs associated with gene expression, plasma proteins, or other traits relevant for
hemostasis using publicly available data. We identiﬁed 112 candidate ASM-SNPs. Of these,
68% were associated with expression of their respective genes in human liver or in other
human tissues and 54% were associated with the respective plasma protein levels, activity,
or other relevant hemostatic genome-wide association study traits such as venous
thromboembolism, coronary artery disease, stroke, and warfarin dose maintenance. Our
studyprovides theﬁrst detailedmapof theDNAmethylation landscapeandASManalysis of
hemostatic genes in human liver tissue, and suggests that methylation regulated by
genetic variants in cis may provide a mechanistic link between noncoding SNPs and
variation observed in circulating hemostatic proteins, prothrombotic diseases, and drug
response.
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Introduction
Plasma concentrations of hemostatic proteins vary in
healthy humans and several hemostatic factors are synthe-
sized in the liver. Characterizing the complex relationship
between genetic, epigenetic (e.g., deoxyribonucleic acid
[DNA] methylation), and transcriptomic variation has the
potential to increase understanding about the mechanisms
regulating hemostasis and to inform drug development. DNA
methylation proﬁles vary among tissues and cell types, thus
analyzing the appropriate tissue is essential. Genetic variants
can exert an inﬂuence on DNA methylation in cis,1,2 which
can then affect cis-regulatory gene expression.3,4 Conse-
quently, it has been suggested that DNA methylation could
provide the link between noncoding genetic variants and
phenotypic variation.
DNAmethylationat cytosine–guaninedinucleotides (CpGs)
is the most studied epigenetic trait and has been most
extensively studied in CpG islands in the promoter of genes,
where it is widely regarded as a mechanism of transcriptional
repression.5,6More recently, however, DNAmethylationwith-
in gene bodies (i.e., exons and introns) has been reported to be
prevalent and to increase gene expression.7–10 Thus, the
relationship between DNA methylation and gene expression
is highly complex and not fully understood.11,12Most methyl-
ation studies have used microarrays that cover<4% of human
CpG sites, and this percentage ismainly biased toward CpGs in
promoters.13,14 The current gold standard method to investi-
gate DNA methylation patterns is bisulﬁte conversion of the
DNA followed by DNA sequencing, which allows determina-
tion of methylation patterns at a single-cytosine resolu-
tion.13,14 Despite the potential of DNA methylation studies
to contribute to new knowledge on gene regulation, high-
resolution DNA methylation data are currently lacking for
hemostatic genes in the liver.
Methylation quantitative trait loci (mQTL) mapping stud-
ies, which link variations in genotypes to DNA methylation
levels at speciﬁc CpG sites across unrelated individuals, is
one approach to elucidatewhether genetic variants correlate
to methylation of genes. Since DNA methylation is also
inﬂuenced by environmental factors (e.g., smoking, diet,
and drugs), large sample sizes are required. As a result,
most mQTL studies to date have been performed in easy to
access tissues such as blood, which is not necessarily the
tissue of relevance. Furthermore, as most mQTL studies have
used microarrays, our understanding of the roles of DNA
methylation within gene bodies is currently limited.15,16
An alternative approach to mQTL is to compare methyla-
tion levels at speciﬁc CpG sites between each of the two
alleles in the same individual. This alternative approach,
referred to as allele-speciﬁcmethylation (ASM), standardizes
environmental and other confounding variables. Therefore,
this is a powerful methodology to map putative cis-acting
single-nucleotide polymorphisms (SNPs) even when using a
small number of samples,17 which facilitates analysis of
“hard to access” human tissues of relevance such as liver.
The ASM approach requires genotyping of SNPs for differen-
tiating the alleles and simultaneous measurements of DNA
methylation at individual CpG sites. Both of these can be
achieved by using targeted next-generation sequencing,
which allows for the unbiased detection of all CpGs, includ-
ing those within the gene body.
To identify novel regulatory elements involved in the
control of hemostatic gene expression in liver we performed
DNA andmethylation sequencing of 35 hemostatic genes. As
far as we are aware, no study has yet reported DNA methyl-
ation patterns on an individual CpG level nor analyzed ASM
in hemostatic genes in human liver tissue samples. Given this
background, the aims of the present study are to: (1) proﬁle
methylation patterns across hemostatic genes in human liver
tissue using targeted bisulﬁte-sequencing; (2) identify ASM-
associated SNPs (ASM-SNPs) in hemostatic genes in human
liver; and (3) determinewhether DNAmethylation regulated
by genetic variation could be a mechanistic link between
noncoding SNPs and variation observed in gene expression,
circulating hemostatic proteins, or other relevant traits.
Methods
Sample Collection and Targeted Sequencing
Tissue collection, genomic DNA (gDNA) and messenger ribo-
nucleic acid (mRNA) extraction, and the target sequencing
(-seq) designs for gDNA and mRNA have been previously
described.18 In short, macroscopically noncirrhotic and non-
tumorous human liver tissue and blood samples were col-
lected from adult patients of European descent (n¼19)
undergoing liver surgery at the Sahlgrenska University Hos-
pital, Gothenburg, Sweden. The institutional review board,
i.e., the Ethics Committee of the University of Gothenburg
approved the collection of the human liver tissues and blood
samples, and their subsequent use for the purpose of this
study. Clinical characteristics of study participants are sum-
marized in►Supplementary Table S1 (available in the online
version). gDNA was isolated from blood for genotyping
(DNA-seq). gDNA and mRNA were simultaneously isolated
from the same piece of liver tissue for methylation (bisulﬁte-
seq) and expression (mRNA-seq) analysis, respectively.
We selected 35 genes that are predominantly expressed in
the liver and are important for hemostasis by studying the
literature, the Kyoto Encyclopedia of Genes and Genomes
pathway database, and the Molecular Signatures Database
(MSigDB, Broad Institute). Custom capture kits (Agilent, Santa
Clara, California, United States) were designed for targeted
sequencing. For full details on gDNA and mRNA sequencing,
dataprocessing, andanalysis, please seeOlssonLindvall et al.18
Targeted Gene Panel for Bisulﬁte-Seq
A SureSelect custom capture kit (Agilent) was designed for
DNA methylation analysis (bisulﬁte-seq) targeting the same
35genes as for gDNAusingAgilent’s SureDesign tool (Agilent).
Probes were designed to capture all exons, introns, and all
potential upstream ( 5kb) and downstream (0.5 kb) regula-
tory regions, resulting in a 3.3-Mb design. Detailed informa-
tion of all regions included in this study is shown in
►Supplementary Table S2 (available in the online version).
gDNA samples from liver were sheared to an average size of
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250 base pair (bp) and bisulﬁte converted with the EZ DNA
methylation kit (Zymo Research, Irvine, California, United
States). The bisulﬁte-treated DNA was then used to prepare
strand-speciﬁc sequencing libraries using the custom-
designed SureSelect kits (Agilent) according to the manufac-
turer’s protocols. All sample librariesweremultiplexed in one
sequence lane on the Illumina HiSeq 2500 with high output
mode and 100bp paired-end reads (Illumina, San Diego,
California, United States), following the manufacturer’s pro-
tocols. Approximately 15M reads were generated per sample
(for coverage per gene see►Supplementary Fig. S1, available
in the online version). Samples from two patients were also
sequenced using SureSelect Methyl-Seq target enrichment
system for Illumina (a commercially available kit fromAgilent
which provides targeted coverage of 84 Mb of the human
genome) to identify possible weaknesses or biases in our
custom-designed kit (prepared as above). Assessment of the
data showed no bias in DNA methylation values between the
two kits, but as expected, coverage was much higher in our
customtargeted-seq samples (►Supplementary Fig. S1, avail-
able in the online version). All raw output sequence reads
were quality controlled using FastQC (https://www.bioinfor-
matics.babraham.ac.uk/projects/fastqc/). After removal of
low-quality bases (Phred score<30), reads were trimmed
(removal of adaptors and indexes) with Trim Galore! (http://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/)
and aligned to the human reference genome (GRCh37/hg19)
with Bowtie2.19 Deduplication and methylation extraction
were performed with the Bismark pipeline (https://www.
bioinformatics.babraham.ac.uk/projects/bismark/) using de-
fault parameters. Finally, SeqMonk (https://www.bioinfor-
matics.babraham.ac.uk/projects/seqmonk/) was used for
visualization.
Detection of ASM
ASM analysis relies on the presence of heterozygous SNPs on
the same read as a given CpG site to separate alleles prior to
analysis. DNA methylation levels at individual CpG sites
between the two alleles are then directly compared. Bisul-
ﬁte-seq reads were aligned to the GRCh37/hg19 reference
genome using Bowtie2. Known SNP positions in the reference
genome were masked by the ambiguity base “N” prior to
alignment to avoid read mapping biases. SNPsplit (https://
www.bioinformatics.babraham.ac.uk/projects/SNPsplit/) was
then used to determine the allelic origin of reads overlapping
SNP positions using individual-speciﬁc genotype information
from the gDNA-seq data. Thus, the data was split into two
in silico allele-speciﬁc aligned genomes. The methylation
status of CpGs was then individually called from the two
separate alignments using Bismark and the methylation level
of each CpG was compared between the two alignments. To
appropriately estimate methylation differences, we required a
minimum of 30 reads per allele. CpGs were deﬁned as ASM
sites if at least one individual had a percent methylation
difference of>20% between the two alleles. The individual
ASM differences wereweighted by their inverse variances and
then summed. The sumwasﬁnally scaled by its standard error
to forma Z-statistic. A p-value of less than 0.05was considered
statistically signiﬁcant. A positive percentage difference value
indicates that the major allele is more methylated than the
minor allele.
Evaluation of ASM Enrichment in Different Genomic
Contexts
We used the right-handed Fisher’s exact test to evaluate if
CpGs displaying ASM were enriched in speciﬁc genomic con-
texts compared with the total number of CpGs in the same
regions. The regions investigated for ASM enrichment were
upstream regions (deﬁned as þ5kb to þ2kb from transcrip-
tion start site [TSS]), promoters (deﬁnedasþ2kb to –1kb from
TSS), ﬁrst exon, remaining exons (excluding the ﬁrst exon),
introns, exon/intron boundaries, CpG islands, and CpG island
shores. A p-value of less than 0.01 was considered statistically
signiﬁcant.
Tag-SNP Extraction from Methyl-Seq Data
Heterozygous SNPs on the same sequencing read as the CpG
sites displaying ASMwere extracted from the gDNA data. For
CpGs with several heterozygous SNPs on the same read, the
closest ones (up to three SNPs per CpG) were selected.
Association of ASM-SNPs tomRNA Expression Levels in
RNA-Seq Data
Given that DNA methylation is linked to the regulation of
gene expression, we assessed whether a difference in allelic
mRNA expression could be identiﬁed based on the ASM-
SNPs. Results from targeted RNA-seq in the same 19 individ-
uals have previously been reported.18 Normalized estimates
of gene expression, that is, transcripts per million were
calculated per gene. We then evaluated all ASM-SNPs for
association to expression levels by linear regression analysis
using additive models in SPSS for Windows version 20 (IBM
Corporation, New York, United States). The statistical signif-
icance cutoff (two-tailed) was 0.05. As this study is based on
only 19 samples, we are underpowered for interindividual
analyses and therefore also report trends (deﬁned as p<0.2).
Association of ASM-SNPs to mRNA Expression in
Publicly Available Expression Quantitative Trait Loci
Data
We next queried all ASM-SNPs and high linkage disequilibrium
(LD) proxies (r20.8 in 1,000 genomes European panel) against
publicly available expression quantitative trait loci (eQTL) data
using PhenoScanner (http://www.phenoscanner.medschl.cam.
ac.uk; assessed May 2019)20 which includes results from the
Genotype-TissueExpressionprojectv6(http://www.gtexportal.-
org/home/datasets),21,22 NHLBI GRASP v2,23 STARNET,24 and
other smaller studies (see http://www.phenoscanner.medschl.
cam.ac.uk/studies/ for details). eQTL results were ﬁltered to
retain only variants with p<1105 and manually curated to
include only eQTLs correlating to the 35 genes of interest.
ASM-SNPs: Association with Circulating Proteins and
Disease Traits
To identify ASM-SNPs associated with circulating plasma
levels or activity of the respective proteins and relevant
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disease and nondisease phenotypes, we queried our variants
and their corresponding proxies (r20.8) against publicly
available genome-wide association study (GWAS) data using
both the PhenoScanner “Proteins” and “Diseases & traits”
search functions (assessedMay 2019) which includes results
from the NHGRI-EBI GWAS catalog (https://www.ebi.ac.-
uk/gwas/) and the UK Biobank (http://www.ukbiobank.ac.
uk). For GWAS, summary statistics were ﬁltered to p<5
105 and then manually curated to retain only entries with
relevant traits. For ASM-SNPs in CPB2 and HAPB2, we sup-
plemented this search with data from our previously pub-
lished GWAS on thrombin-activatable ﬁbrinolysis inhibitor
(encoded by CPB2)25 and factor-seven activating protease
(FSAP, encoded by HABP2).26
Validation of ASM-SNPs in mQTL Data Sets
As away to validate our ﬁndings, ASM-SNPs and correspond-
ing proxies (r20.8 in 1,000 genomes European panel)
were queried against publicly available mQTL data using
PhenoScanner “Epigenetics” search function which includes
data from BIOS QTL browser (https://genenetwork.nl/
biosqtlbrowser/), BLUEPRINT Epigenome (http://www.blue-
print-epigenome.eu/), and Gaunt et al.27 The output result
list was ﬁltered to p<5105 and manually curated to
retain only mQTL entries.
Annotation and Functional Prediction of Variants
Database of Single Nucleotide Polymorphisms (dbSNP; build
150, available from http://www.ncbi.nlm.nih.gov/SNP/) was
used to annotate SNPs. HaploReg v4.128 was used to deter-
mine the chromatin state in liver tissue per ASM-SNP haplo-
type block. The default 15-state core ChromHMMmodel and
H3K4me1/H3K4me3 peaks from Roadmap Epigenomics29
were used to identify enhancers and promoters. Results
weremanually curated to retain only variantswith predicted
enhancer or promoter chromatin states in liver tissue.
Results
DNA Methylation Pattern and ASM of Hemostatic
Genes in Human Liver
Wemeasured the DNAmethylation status of each individual
CpG in all 35 hemostatic genes including at least 5 kb
upstream and 0.5 kb downstream of each gene. In total,
8,707 unique CpG sites were captured in our design
(1.2Mb in total). The density of CpG sites in each gene varied
between 2 CpGs (F13B) and 30 CpGs (F7) per kbp, with a
median density of 6 CpGs per kbp. Schematic illustrations of
DNA methylation patterns for VKORC1 (encoding vitamin K
reductase complex subunit 1), F2 (thrombin), and F10 (factor
X) are displayed in ►Fig. 1 and for the remaining genes in
►Supplementary Fig. S2 (available in the online version).
Using the ASMapproach,we identiﬁed151 CpGs displaying
an allelic methylation imbalance of 20% or more in at least
one sample, and 116 of thesewere signiﬁcant (p<0.05). These
CpGs were found in 24 of the 35 genes analyzed and were
associated with 112 SNPs (►Table 1). The number of CpGs
displaying ASM per gene varied between one (e.g., in VKORC1)
to 15 (e.g., in SERPINF2). A schematic viewofASMpositions per
gene is displayed in ►Fig. 1 and in ►Supplementary Fig. S2
(available in the online version). The exact positions of the
ASM-CpGs, the degree of ASM, dbSNP ID of the ASM-SNPs,
number of heterozygous samples, and associations of ASM-
SNPs with mRNA expression, levels/activity of circulating
proteins, and other GWAS traits with relevance for hemostasis
are reported in ►Tables 2–4. The ASM association results are
presented in these three tables based on whether or not the
ASM-SNPs have previously been identiﬁed as eQTLs. Allelic
methylation for all CpGs (including nonsigniﬁcant ASM-CpGs)
and further details on associations are shown in
►Supplementary Table S3 (available in the online version).
Forest plots of methylation differences between alleles in all
151 CpGs per individual are displayed in ►Supplementary
Fig. S3 (available in the online version). A UCSC browser track
for signiﬁcant ASM positions is available to the research
community at: https://genome.ucsc.edu/s/marcela.davila%
40gu.se/ASM_CJern.
CpGs Displaying ASM are Enriched in the First Exon
To evaluate if ASM is overrepresented in speciﬁc genomic
contexts, we performed an enrichment test comparing ASM-
CpGs with all CpGs in different regions. The only regionwith
a signiﬁcant over-representation of ASM was “ﬁrst exon”
(p¼0.0007, Fisher’s exact test).
Eight ASM-SNPs Associated with mRNA Expression in
RNA-Seq Data
To determine whether DNA methylation regulated by genetic
variants in cis could provide the mechanistic link between
genetic variants associated with gene expression, we used
mRNA-seq data (derived from the same individuals and the
same liver tissue samples as used in ASM analysis) to assay
potential differences in expression based on genotype of the
ASM-SNP. A total of eight ASM-SNPs were signiﬁcantly associ-
atedwithallelicdifferences inexpression (p<0.05): four in the
gene encoding protein Z (PROZ), one in the gene encoding
VKORC1, one in the gene encoding thrombin, and two in the
gene encoding kininogen 1 (KNG1) (►Fig. 2;►Tables 2 and 3).
A trend was observed for a further 22 ASM-SNPs (9 at p<0.1
and 13 ASM-SNPs at p<0.2; see online ►Supplementary
Fig. S4, available in the online version).
Seventy-Six ASM-SNPs Associated with mRNA
Expression in Publicly Available eQTL Data
WenextqueriedtheASM-SNPs inpubliclyavailableliver tissue
eQTLdatausingPhenoScanner. A total of 22ASM-SNPs (orhigh
LD proxies) were identiﬁed as eQTLs in liver tissue for their
respective gene (►Table 2). These included four SNPs in PROZ
and one SNP in VKORC1 for which we found a signiﬁcant
association with mRNA expression using our RNA-seq data
(►Fig. 2A–D and E, respectively) and ﬁve others with a trend
for association. The same alleles associated with higher gene
expression in liver tissue eQTL studies were expressed at
higher levels in our RNA-seq data (data not shown).
While many cis-acting genetic variants are speciﬁc for a
given tissue, others may be common to several tissues.22
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Further, sample size greatly affects eQTL mapping and thus
more readily available tissues tend to have more reported
eQTLs.22 In line with this, an additional 54 ASM-SNPs (or
proxies) were eQTLs for their respective genes in other
tissues in a total of 17 genes (►Table 3). This included four
SNPs in PROZ, one in F2, and two in KNG1, signiﬁcantly
associated with expression using our normalized RNA-seq
data (►Fig. 2F–H), and 13 other SNPs showing a trend for
association in our data (►Supplementary Fig. S4, available in
the online version). A complete list of all eQTL associations
from all tissues can be found in ►Supplementary Table S4
(available in the online version).
For 36 ASM-SNPs (corresponding to 16 genes), no geno-
type-expression associations have previously been reported
(►Table 4). Of these, three ASM-SNPs exhibited a trend for
association with expression using our normalized RNA-seq
data for PROZ and the genes encoding factor V (F5) and α-2-
plasmin inhibitor (SERPINF2).
Thirty-Three ASM-SNPs Associate with Circulating
Proteins; 36 with Other Relevant GWAS Traits
To determine whether allele-speciﬁc DNA methylation also
could affect protein abundance, we assessed ASM-SNPs for
association with circulating levels or activity of plasma
proteins using publicly available protein quantitative trait
loci (pQTL) and GWAS data sets. A total of 33 ASM-SNPs (or
proxies) were previously associated with the respective
protein concentration or activity (►Tables 2–4, details in
►Supplementary Table S3, available in the online version),
and these included 5 ASM-SNPs with no previous reported
eQTLs that were associated with plasma ﬁbrinogen, KNG1,
SERPINF2, and FSAP levels (►Table 4). A complete list of pQTL
associations can be found in ►Supplementary Table S5
(available in the online version).
We next assessed association of ASM-SNPs with relevant
disease and nondisease phenotypes in PhenoScanner. One
ASM-SNP in VKORC1 was associated with warfarin dosage
levels (rs8050894).30Atotal of fourASM-SNPswere associated
with complex diseases (two SNPs in F5with venous thrombo-
embolism [rs3766110, rs3766111; http://www.ukbiobank.ac.
uk], one SNP in TFPI with coronary artery disease
[rs8176546],31 and one in F2 with stroke [rs2070851]32). A
total of 33 ASM-SNPs were associated with other related
phenotypes. A complete list of GWAS associations can be
found in ►Supplementary Table S5 (available in the online
version).
Fig. 1 Deoxyribonucleic acid (DNA) methylation patterns of selected hemostatic genes in human liver tissue. For each gene, gene structure
(blue) and cytosine–guanine dinucleotide (CpG) islands (red) are displayed on top. At least 5 kb upstream and 0.5 kb downstream of each gene
are included. The methylation status for all CpGs is displayed, where purple represents a low degree of methylation and green a high degree of
methylation. Methylation values are based on the average of the 19 samples. CpGs displaying allele-speciﬁc methylation (ASM) in one or more
samples are denoted by asterisks. (A) VKORC1; (B) F2; and (C) F7 and F10. All other genes can be found in►Supplementary Fig. S2 (available in the
online version).
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Overlap between ASM-SNPs and Previously Identiﬁed
mQTL SNPs
We queried our ASM-CpGs against the publicly available
mQTL microarray-based data using PhenoScanner. Only six
of the CpGs displayingASM in our study design are located on
commercially availablemicroarrays. However, all six of these
were identiﬁed as mQTLs with the same SNP-CpG associa-
tion as in our study, although in other tissue types than liver.
Therefore, all remaining ASM-CpGs identiﬁed here are
completely novel genotype-associated methylation sites,
and all associations reported in this study are novel in liver
tissue.
Discussion
In this study, we analyzed DNA methylation proﬁles of 35
hemostatic genes that are predominantly expressed in liver.
To the best of our knowledge, this is theﬁrst study presenting
DNA methylation patterns of hemostatic genes on an indi-
vidual CpG level in human liver. We identiﬁed ASM in 24 of
the 35 targeted genes. In addition, we demonstrated associ-
ations between ASM-SNPs and mRNA expression as well as
association with circulating hemostatic proteins, relevant
complex traits (e.g., coronary artery disease, stroke, venous
thromboembolism), and drug dosing (e.g., warfarin). Our
ﬁndings highlight the importance of genetic–epigenetic
interactions and suggest that methylation regulated by
genetic variants could provide the mechanism by which
SNPs exert an effect on circulating hemostatic proteins,
prothrombotic diseases, and drug response.
As discussed in the Introduction, previous studies that
link variations in genotypes to DNA methylation levels at
speciﬁc CpG sites across individuals (mQTL) require large
sample sizes and have most often been performed in easy to
access tissues such as blood. Here, we used ASM analysis,
which has an advantage over mQTL analyses as it uses a
within-sample control (the other allele) to query effects of
SNPs on DNA methylation. In doing so, the ASM approach is
more robust to environmental and experimental effects and
thusmore sensitive than standardmQTL analysis.33Wewere
therefore able to use human liver tissue, the main biological
source of the hemostatic proteins studied here, to map
putative cis-acting polymorphisms despite having a small
number of samples.17 ASM-SNPs and corresponding proxies
were queried against publicly available mQTL data as a way
to validate our ﬁndings. However, as nearly all published
human mQTL studies have used commercially available
microarrays that interrogate only a small portion of all
CpGs, only eight CpGs in our study design are represented
in mQTL data. Six of these displayed ASM in our data, and all
of these were identiﬁed as mQTLs with the same SNP-CpG
association as in our study, although in other tissue types
than liver. Ideally, we would compare our ASM results with
another similar bisulﬁte-seq data set in liver, but such data is
not available at this time as far as we are aware.
The hemostatic genes analyzed in this study all had
a low degree of methylation around promoters, as
expected for actively transcribed genes (►Fig. 1 andTa
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►Supplementary Fig. S2, available in the online version). The
methylation level in gene bodies was generally much higher,
although this varied more than the promoter methylation
(►Fig. 1 and►Supplementary Fig. S2, available in the online
version). Previous mQTL studies in a variety of tissues have
demonstrated that cis-acting methylation-associated SNPs
are enriched in regulatory chromatin domains and transcrip-
tion factor binding sites, and colocalize with eQTLs.11,34–37
Further, CpG sites that are associated with expression levels
have previously been shown to be enriched in enhancers,
Table 2 CpGs displaying signiﬁcant ASM (p< 0.05) and associated SNPs (ASM-SNPs) previously reported as liver eQTLs in public
databases, and associations of the ASM-SNPs to mRNA expression in liver tissue, to circulating protein levels of the respective
genes, and to other GWAS traits relevant for hemostasis
ASM SNP Associations
Gene CpG location No. het. % ASM diff. dbSNP Distance from
CpG (bp)
mRNA pQTL GWAS
C4BPB chr1:207269856 1 21 rs8942 63 Yesb
CPB2 chr13:46644103 2 9 rs9534307 27 Yesb Yes
CPB2 chr13:46649378 1 27 rs9567613 20 Yesb Yes
CPB2 chr13:46669605 1 21 rs7991899 55 Yesb Yes
CPB2 chr13:46683614 2 10 rs7338061 19 Yesb Yes
F10 chr13:113784439a 1 23 rs693335 4 Yes Yes
F10 chr13:113784452 1 20 rs693335 9 Yes Yes
F10 chr13:113784460 1 25 rs693335 17 Yes Yes
F10 chr13:113784466 1 26 rs693335 23 Yes Yes
F10 chr13:113784481 1 22 rs693335 38 Yes Yes
F10 chr13:113784497 1 23 rs693335 54 Yes Yes
F10 chr13:113784499 1 25 rs693335 56 Yes Yes
F7 chr13:113757759 2 12 rs3093229 67 Yes Yes
F7 chr13:113759695 1 25 rs510317 59 Yes Yes
F7 chr13:113761451 2 24 rs28663357 62 Yesb Yes
F7 chr13:113761585a 2 15 rs142493427 5 Yes
PROC chr2:128174852 1 28 rs2069901 9 Yes
PROC chr2:128174852 1 28 rs2069902 11 Yes
PROC chr2:128176028 9 6 rs1799810 12 Yes
PROC chr2:128177360 8 11 rs1158867 17 Yes
PROZ chr13:113817559 1 45 rs2480948 22 Yes NA Yes
PROZ chr13:113818668 2 24 rs3024731 40 Yes NA Yes
PROZ chr13:113819002 5 26 rs494860 7 Yes NA Yes
PROZ chr13:113819008 5 27 rs494860 1 Yes NA Yes
PROZ chr13:113819050 2 29 rs494860 41 Yes NA Yes
PROZ chr13:113819074a 2 18 rs494860 65 Yes NA Yes
PROZ chr13:113824222 1 32 rs1755690 44 Yes NA Yes
SERPINA1 chr14:94844610 1 24 rs2073333 48 NA
SERPINA1 chr14:94844885 1 31 rs1303 42 NA
TFPI chr2:188340376 4 11 rs8176546 20 NA Yes
VKORC1 chr16:31104505 3 47 rs8050894 4 Yes NA Yes
Abbreviations: ASM, allele-speciﬁc DNA methylation; bp, base pairs; CpG, cytosine-guanine site; dbSNP, Database of Single Nucleotide Poly-
morphisms; DNA, deoxyribonucleic acid; eQTL, expression quantitative trait loci; GWAS, genome-wide association study; mRNA, messenger
ribonucleic acid; pQTL, protein quantitative trait loci; SNP, single-nucleotide polymorphism.
Note: No. het., number of heterozygous samples; % ASM diff., mean percent methylation difference between major and minor alleles of all
heterozygous samples. A positive percent difference indicates higher methylation level on the major allele.
aCpG included on commercial DNA methylation microarrays.
bNonsigniﬁcant (p> 0.05) trend for association with mRNA expression in in-house mRNA-seq data.
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Table 3 CpGs displaying signiﬁcant ASM (p< 0.05) and associated SNPs (ASM-SNPs) previously reported as eQTLs in tissue types
other than liver, and association of these ASM-SNPs to mRNA expression in liver tissue (RNA-seq data), to circulating protein levels
of the respective genes (pQTL), and to other GWAS traits relevant for hemostasis
ASM SNP Associations
Gene CpG location No. het. % ASM diff. dbSNP Distance from
CpG (bp)
mRNA pQTL GWAS
A2M chr12:9230027 7 18 rs2377682 11 NA
A2M chr12:9259915 6 10 rs226389 8 Yesb NA
A2M chr12:9279617 7 6 rs226372 19 Yesb NA
CPB2 chr13:46627428 8 28 rs1087 11 Yesb Yes
CPB2 chr13:46627428 8 28 rs940 52 Yes
CPB2 chr13:46627473 4 23 rs940 7 Yes
CPB2 chr13:46627504 3 12 rs940 24 Yes
CPB2 chr13:46649378 1 27 rs1022952 30 Yes
F10 chr13:113784564 1 36 rs776906 24 Yes Yes
F10 chr13:113784692 1 21 rs2480946 28 Yes Yes
F10 chr13:113784702 1 24 rs2480946 18 Yes Yes
F10 chr13:113776916a 4 11 rs563964 31 Yesb Yes
F10 chr13:113776916a 4 11 rs3211717 33 Yesb Yes
F13B chr1:197026831 10 8 rs17549312 15 Yes
F13B chr1:197026871 6 12 rs17549312 25 Yes
F2 chr11:46744514 2 17 rs2070851 14 NA Yes
F2 chr11:46747073 1 50 rs3136460 8 Yes NA Yes
F5 chr1:169493712 1 25 rs9332641 1 Yes Yes
F5 chr1:169493712 1 25 rs9332640 14 Yes
F5 chr1:169515148 1 27 rs3766110 35 Yes
F5 chr1:169515148 1 27 rs3766111 56 Yes
F5 chr1:169533986 1 21 rs724507 42
F5 chr1:169555972 1 25 rs2269648 78
FGB chr4:155486657 3 12 rs2227403 11 Yes
KNG1 chr3:186435526 1 22 rs13072823 35 Yes Yes
KNG1 chr3:186440466 2 16 rs1648714 17 Yes Yes
KNG1 chr3:186449900 6 6 rs1622922 16 Yesb Yes
KNG1 chr3:186449900 6 6 rs1648699 10 Yesb Yes
KNG1 chr3:186449900 6 6 rs1648700 16 Yesb Yes
KNG1 chr3:186452968 2 19 rs822363 23 Yes
KNG1 chr3:186434963 2 16 rs5029973 76 Yes Yes
PLG chr6:161135056 2 11 rs3757019 55 Yesb
PLG chr6:161137753 2 16 rs14224 26 Yesb
PROC chr2:128182990 8 29 rs2069924 4 Yes
PROC chr2:128147838 7 8 rs13029237 16 Yes
PROC chr2:128148742 6 22 rs35708549 22
PROC chr2:128148776 8 27 rs35708549 12
SERPINA1 chr14:94843725 1 23 rs11628917 6 NA Yes
SERPINA1 chr14:94852549 1 25 rs1980617 15 NA Yes
SERPINA1 chr14:94852749 2 16 rs75285293 47 NA
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gene bodies, CpG island shores, and in the ﬁrst exon, but not
in promoter regions.8,38 In line with this, we found that the
majority of the ASM-CpGs/SNPs were located within gene
bodies (i.e., 102 out of 144) and identiﬁed an enrichment of
ASM in the ﬁrst exon. Additionally, nearly all (94%) of the
ASM-SNPs had chromatin states indicative of promoter
and/or enhancer elements in liver (►Supplementary
Table S6, available in the online version). Taken together,
we present the ﬁrst detailed map of the DNA methylation
landscape in hemostatic genes in human liver tissue, and our
study underscores the importance of more mechanistic
studies on the role of methylation in gene bodies.
Table 3 (Continued)
ASM SNP Associations
Gene CpG location No. het. % ASM diff. dbSNP Distance from
CpG (bp)
mRNA pQTL GWAS
SERPINA1 chr14:94858368 2 12 rs1610317 12 NA Yes
SERPINA10 chr14:94755152 2 22 rs12434093 32 Yes
SERPINA10 chr14:94755217 1 21 rs12434093 33 Yes
SERPINA10 chr14:94755230 1 32 rs12434093 46 Yes
SERPINA10 chr14:94760975 5 9 rs3827897 10 Yes
SERPINA5 chr14:95050296 2 22 rs12880862 12
SERPINA5 chr14:95051504 1 40 rs12886695 64
SERPINA5 chr14:95047617 2 12 rs11847476 12 Yesb
SERPINA5 chr14:95047617 2 12 rs11847477 9
SERPIND1 chr22:21129590 1 25 rs165680 31 Yesb NA
SERPINF2 chr17:1648204 1 32 rs2070862 90
SERPINF2 chr17:1650172 1 40 rs117378188 31 Yesb
SERPINF2 chr17:1658948 1 23 rs4566204 20
SERPINF2 chr17:1658955 1 26 rs4566204 13
SERPINF2 chr17:1636455 1 29 rs11657222 22 Yesb
SERPINF2 chr17:1640652a 1 46 rs62090051 12
SERPINF2 chr17:1640661 1 36 rs62090051 21
SERPINF2 chr17:1640674 1 44 rs62090051 34
SERPINF2 chr17:1640674 1 44 rs1045794 35 Yesb
SERPINF2 chr17:1640710 1 30 rs62090051 70
SERPINF2 chr17:1640710 1 30 rs1045794 1 Yesb
SERPINF2 chr17:1640788 11 7 rs8077638 5 Yes
SERPINF2 chr17:1640794 1 31 rs1045794 85 Yesb
SERPINF2 chr17:1640794 1 31 rs8077638 1 Yes
SERPINF2 chr17:1640812 10 10 rs8077638 19 Yes
SERPINF2 chr17:1640830 4 18 rs8077638 37 Yes
SERPINF2 chr17:1640868 1 21 rs8077638 75 Yes
SERPINF2 chr17:1645507 5 14 rs62090057 19
SERPING1 chr11:57374280 1 22 rs11603020 52 Yesb Yes
TFPI chr2:188340376 4 11 rs8176547 27 NA
TFPI chr2:188353789 1 36 rs8176500 35 NA
Abbreviations: ASM, allele-speciﬁc DNA methylation; bp, base pairs; CpG, cytosine-guanine site; dbSNP, Database of Single Nucleotide Poly-
morphisms; DNA, deoxyribonucleic acid; eQTL, expression quantitative trait loci; GWAS, genome-wide association study; mRNA, messenger
ribonucleic acid; pQTL, protein quantitative trait loci; SNP, single-nucleotide polymorphism.
Note: No het, number of heterozygous samples; % ASM diff., mean percent methylation difference between major and minor alleles of all
heterozygous samples. A positive percent difference indicates higher methylation level on the major allele.
aCpG included on commercial DNA methylation microarrays.
bNonsigniﬁcant (p> 0.05) trend for association with mRNA expression in in-house RNA-seq data.
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Table 4 CpGs displaying signiﬁcant ASM (p<0.05) and associated SNPs (ASM-SNPs) not reported as eQTLs in public databases, and
associations of ASM-SNPs to mRNA expression in liver tissue (RNA-seq data), to circulating protein levels of the respective genes
(pQTL), and to other GWAS traits relevant for hemostasis
ASM SNP Associations
Gene CpG location No. het. % ASM diff. dbSNP Distance from CpG (bp) mRNA pQTL GWAS
F10 chr13:113784664 1 31 rs3211742 20
F13B chr1:197026871 6 12 rs1759008 24 Yes
F2 chr11:46743111 4 17 rs3136439 24 NA
F5 chr1:169515447 1 42 rs749045929 29
F5 chr1:169515447 1 42 rs3835453 25
F5 chr1:169515447 1 42 rs796545997 27 Yesb Yes
F5 chr1:169515447 1 42 rs112177003 1
F5 chr1:169529841 1 24 rs6022 15
F7 chr13:113759695a 1 25 rs510335 60
F7 chr13:113761585a 2 15 rs2515646 17
FGB chr4:155480425 1 21 rs7673587 9 Yes
HABP2 chr10:115310488 5 9 rs2000277 26
HABP2 chr10:115310548 6 12 rs3758591 4 Yes
HABP2 chr10:115310548 6 12 rs3758590 15
HABP2 chr10:115316814 1 32 rs4918842 2
HABP2 chr10:115327006 1 23 rs11575665 34
HABP2 chr10:115327006 1 23 rs11575666 42
HABP2 chr10:115330374 7 56 rs7079148 12
HABP2 chr10:115332849 10 33 rs7101144 1
HABP2 chr10:115334080 2 13 rs3740530 44 Yes
HABP2 chr10:115336796 1 24 rs2302374 38
HRG chr3:186383214 1 21 rs9814412 34 Yes
KNG1 chr3:186442126 1 20 rs1648712 83 Yes
KNG1 chr3:186445048 2 16 rs2304456 4 Yes Yes
KNG1 chr3:186445221 2 30 rs3841557 35
KNG1 chr3:186445221 2 30 rs5030025 16 Yes
PLG chr6:161126010 1 22 rs1819138 64
PLG chr6:161126030 1 35 rs1819138 44
PLG chr6:161168694 1 27 rs10625439 41
PROC chr2:128148742 6 22 rs79819102 1
PROC chr2:128148776 8 27 rs79819102 35
PROS1 chr3:93605725 1 45 rs8178648 14 NA
PROZ chr13:113817557 1 49 rs45538837 2 NA Yes
PROZ chr13:113817559 1 45 rs45538837 4 NA Yes
PROZ chr13:113818958 2 16 rs3024733 44 NA
PROZ chr13:113819002 5 26 rs3024733 0 NA
PROZ chr13:113819008 5 27 rs3024733 6 NA
PROZ chr13:113819093 1 23 rs3024782 65 Yesb NA
PROZ chr13:113819101 1 25 rs3024782 57 Yesb NA
SERPINA5 chr14:95048706 1 27 rs112795992 1
SERPIND1 chr22:21132447 2 32 rs75917143 9 NA
SERPINF2 chr17:1650172 1 40 rs6502935 4 Yesb Yes
Abbreviations: ASM, allele-speciﬁc DNA methylation; bp, base pairs; CpG, cytosine-guanine site; dbSNP, Database of Single Nucleotide Poly-
morphisms; DNA, deoxyribonucleic acid; eQTL, expression quantitative trait loci; GWAS, genome-wide association study; mRNA, messenger
ribonucleic acid; pQTL, protein quantitative trait loci; SNP, single-nucleotide polymorphism.
Note: No. het., number of heterozygous samples; % ASM diff., mean percent methylation difference between major and minor alleles of all
heterozygous samples. A positive percent difference indicates higher methylation level on the major allele.
aCpG included on commercial DNA methylation microarrays.
bNonsigniﬁcant (p> 0.05) trend for association with mRNA expression in in-house RNA-seq data.
Thrombosis and Haemostasis Vol. 120 No. 2/2020
Allele-Specific Methylation of Hemostatic Genes Olsson Lindvall et al.238
We found that 68% of our ASM-SNPs had previously been
associated with expression of their respective genes in
publicly available eQTL databases. However, only a minority
(22 of 76) were liver eQTLs. Thus, the ASM-SNPs were also
tested for association to expression using RNA-seq data from
our liver samples. We report both signiﬁcant associations
and trends.We are aware that such an analysis should ideally
be adjusted for multiple testing. However, as we were
underpowered for inter-individual analysis, we believe this
is an appropriate ﬁrst step as we used the tissue of rele-
vance.39 In addition to coming from the same individuals,
DNA methylation and RNA analyses were analyzed from the
same tissue samples (i.e., DNA and RNA were extracted
simultaneously, with the same exact cell composition) in
our study which can facilitate the investigation of the func-
tional relationship between DNA methylation and gene
expression.40 In support of our RNA-seq results, all signiﬁ-
cant associations were previously reported eQTLs (ﬁve in
liver and three in other tissues). Of the 22 ASM-SNPs with a
trend for association, 19 were previously reported eQTLs (6
in liver and 13 in other tissues). Therefore, despite using so
few samples, our study supports many published eQTLs for
hemostatic genes, even those initially identiﬁed in other
tissues, and provides validity to our study design.
eQTLs tend to be found in promoter regions, whereas
mQTLs and cis-ASM positions tend to occur in other regula-
tory regions such as enhancers and insulators.33 Previous
studies have found only a small overlap between variants
tagging cis-acting DNA methylation and expression (i.e.,
mQTLs and eQTLs).11,15,27,41–43 We recently performed a
genotype-expression study by analyzing allele-speciﬁc ex-
pression (ASE) of the same 35 hemostatic genes in the same
sample used in the present study.18 We compared all ASM-
SNPs and ASE-SNPs (including corresponding proxies) iden-
tiﬁed in both studies and found only 10 SNPs in common
(< 1%). As ASE analyses are limited to exonic SNPs (i.e., SNPs
need to be present on RNA), whereas ASM is based on CpG
sites that are located primarily in upstream regulatory
regions and introns, these two analyses represent comple-
mentary approaches to identify novel cis-regulatory var-
iants. Taken together, the results from our previous and
present study highlight the complimentary nature of con-
ducting both types of mapping.
Given the range of processes that affect protein abundance,
a SNP inﬂuencing DNAmethylation andmRNA levels may not
necessarily inﬂuence the protein level. To address whether
DNA methylation regulated by SNPs in cis could provide the
mechanistic link between SNPs previously associated with
circulating hemostatic proteins, we intersected the ASM-SNPs
(or high LDproxies)with public pQTL andGWASdata. As far as
we are aware, pQTL or GWAS protein data (for SNPs in the
respective gene) is only available for 16 of the 24 genes
displaying ASM in our study. For 12 of these genes (75%), the
SNPs associatedwith protein levels in the public datawere the
same as the ASM-SNPs (associated with CpG methylation)
identiﬁedhere. Although this analysis suggests a potential role
for many of the ASM-SNPs in regulation of plasma proteins, it
should be emphasized that further replication of our results
and other functional validation studies are warranted.
In the era of personalized therapy, several clinical trials
are investigating the value of genotype-guided dosing of the
most commonly used oral anticoagulants, for example, war-
farin, and nonvitamin K antagonist oral anticoagulants
(NOACs).44–46 Studies are also emerging that demonstrate
that DNAmethylation changes contribute to the variability of
response to warfarin,47 aspirin, and clopidogrel.48 Interest-
ingly and in line with this, we identiﬁed ASM CpG-SNP pairs
in VKORC1 which is a target for warfarin, and in F2 and F10
which both are targets for NOACs. We also identiﬁed ASM
CpG-SNP pairs in 11 other hemostatic genes that are current
targets of approved antithrombotic, antiﬁbrinolytic, and
other related drugs.49 The ASM-SNP in VKORC1 is an eQTL
A
B
C
D F H
E G
Fig. 2 Box plots of genotype versus messenger ribonucleic acid (mRNA) expression level. Allele-speciﬁc methylation-single-nucleotide
polymorphisms (ASM-SNPs) signiﬁcantly associated to expression of the respective gene based on normalized RNA-seq data from 19 human liver
samples (p< 0.05). Subjects homozygous for the major allele had higher gene expression of PROZ (A–D); VKORC1 (E); F2 (F); and KNG1 (G, H).
TPM, transcripts per million. 0¼ homozygous major allele, 1¼ heterozygous, 2¼ homozygous minor allele. Plots for ASM-SNPs showing a trend
for association to expression (p< 0.2) can be found in ►Supplementary Fig. S2 (available in the online version).
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SNP in liver for VKORC1 expression, was associated with
mRNA expression in our study (p¼0.009), and is the top hit
in a GWAS for “warfarin maintenance dose.”30 The ASM-CpG
associatedwith this SNP displayed one of the highest degrees
of ASM in our study, with a percentmethylation difference of
47% in favor of the minor allele. A SNP in almost perfect LD
with the ASM-SNP has already been used in pharmacoge-
netics-based clinical trials for warfarin with promising
results in European populations.44 Thus, methylation inﬂu-
enced by genetic variation in cis may not only provide a
mechanistic link between the noncoding genetic changes
and phenotypic variation observed in circulating hemostatic
proteins and prothrombotic diseases but also in response to
drugs.
Apart from the methodological strengths of the ASM
approach described above,we usedN-masked individualized
genomes based on gDNA-seq data to prevent alignment bias
which is otherwise a common source of error in ASM
analysis. Additionally, the custom target sequence design
used here providesmuch deeper coverage across the genes of
interest compared with whole genome bisulﬁte-seq. Despite
these strengths, there are some limitations which deserve
mention. (1) The targeted design we chose was limited to
approximately 5 kb upstream and 0.5 kb downstream of each
gene, which means we could have missed important SNPs or
CpGs outside of these regions. However, it is of note that our
design still provides a great enrichment compared with
commonly used array-based analyses. (2) Although the
ASM approach is powerful, our study is based on just 19
samples and increasing the number of samples may reveal
many more CpG-SNP associations. (3) We used conventional
(short-read) Illumina sequencing. To assess for ASM, one
must obtain both allelic andmethylation signals on the same
sequencing read. Therefore, using a platform that produces
longer reads (e.g., single-molecule real-time bisulﬁte se-
quencing)50 may reveal further CpG-SNP associations. (4)
Liver tissue consists of multiple cell types that may have
different methylation proﬁles, and we recognize that we
cannot determine from which cell type the identiﬁed allelic
imbalances originates using this study design. (5) Addition-
ally, it should be emphasized that the results were generated
in samples from subject with European ancestry, and our
ﬁndings many not be generalizable to populations of differ-
ent ethnicity.
In conclusion, we identiﬁed 112 genetic variants associ-
ated with DNA methylation in hemostatic genes in human
liver tissue. Of these ASM-SNPs, 78% were associated with
expression of their respective genes, or with their respective
protein levels or activity, or with other relevant hemostatic
GWAS traits, suggesting that methylation regulated by ge-
netic variants may provide a mechanistic link between
noncoding SNPs and variation observed in circulating hemo-
static proteins, prothrombotic diseases, and drug response.
Our study highlights the importance of interaction analysis
between genetic and epigenetic variation in relevant tissues,
and that this approach can contribute to new insights into
the biological processes affecting thrombosis and
hemostasis.
What is known about this topic?
• Characterizing the complex relationship between ge-
netic, epigenetic (e.g., DNA methylation), and tran-
scriptomic variation has the potential to increase
understanding about the mechanisms regulating he-
mostasis and inform drug development.
• Several hemostatic factors are synthesized in the liver.
Despite DNA methylation being the most studied
epigenetic trait, most studies are based on arrays
that cover<4% of CpG sites. Thus, no high-resolution
information on DNAmethylation is currently available
for hemostatic genes in liver.
• Single-nucleotide polymorphisms (SNPs) can exert an
inﬂuence on DNA methylation in cis which can affect
gene expression. This can be analyzed through allele-
speciﬁc methylation (ASM) experiments.
What does this paper add?
• We used a targeted bisulﬁte-sequencing approach to
allow for the unbiased detection of all CpGs across 35
hemostatic genes and present the ﬁrst high-resolution
DNA methylation map for these genes in human liver.
• We identiﬁed 112 candidate ASM-SNPs in 24 hemo-
static genes, all representing novel genotype-methyl-
ation associations in liver tissue. Of these SNPs, 76
were previously associated with gene expression and
61 were previously associated with circulating hemo-
static proteins, relevant complex traits (e.g., coronary
artery disease, stroke, venous thromboembolism), and
drug dosing (e.g., warfarin).
• This suggests that methylation regulated by SNPs in cis
may provide a mechanistic link between noncoding
SNPs and variation observed in hemostatic gene ex-
pression, circulating hemostatic proteins, prothrom-
botic diseases, and drug response.
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